ABOUT

Syncona are a FTSE 250 biotech investment company that find, build and fund companies to translate exceptional science into transformational treatments for patients in areas of high unmet need.

Focused on building the next generation of global leaders in life science, Syncona’s investment model has been developed to build long term sustainable growth by supporting their portfolio companies from scientific research to commercialisation.